Stein Steven H

Stein Steven H, EVP & Chief Medical Officer, has demonstrated a clear selling bias in his transactions involving Incyte Corporation (INCY), with no recent purchases and consistent disposals over the past two years. Since January 2024, Stein has executed eight sales totaling approximately $12.02 million, with notable transactions including a $1.59 million sale on January 5, 2026, and a $2.06 million sale on December 2, 2025. Smaller but significant disposals, such as $534,812 on November 5, 2025, and $251,785 on July 21, 2025, further reinforce this trend. The transactions appear systematic, with multiple sales occurring in close succession, such as the combined $1.74 million and $263,474 sales on December 1, 2025. Stein’s activity also includes periodic acquisitions through derivative securities, marked as "A" (award) or "F" (tax withholding), though these are non-discretionary and tied to equity compensation. For example, on July 15, 2025, he received awards with no reported market value, while tax-related transactions, such as a $108,927 withholding on the same date, indicate routine equity vesting. Despite these holdings, the overwhelming direction of Stein’s trades leans toward liquidation, with no open-market buys offsetting the substantial sell-side activity. The consistency and scale of these disposals suggest a deliberate reduction in his INCY position over time.